Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Langer

Showing results (101-110 of 199) with videos related to

Pageof 20
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of ExcellenceV Grøndahl, T Binderup, S W Langer, et al.
Lung Cancer (Amsterdam, Netherlands)|September 1, 1996
Brain relapses in chemotherapy-treated small cell lung cancer: a retrospective review of two time-dose regimens of therapeutic brain irradiationF Bach, J B Sørensen, L Adrian, et al.
Diagnostics (Basel, Switzerland)|May 11, 2024
Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu/<sup>225</sup>AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the PancreasElisabetta Perrone, Kriti Ghai, Aleksandr Eismant, et al.
Ugeskrift for Laeger|March 15, 1993
[The value of bone marrow scintigraphy in patients with recurrent breast cancer]S W Langer, C Kamby, H S Thomsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 2022
Prospective Phase II Trial of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET/CT Imaging of Integrin α<sub>v</sub>β<sub>3</sub> for Prognostication in Patients with Neuroendocrine NeoplasmsEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2020
Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trialMorten Quist, Seppo W Langer, Christian Lillelund, et al.
Journal of Neuroendocrinology|June 27, 2024
NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasmsH Sorbye, G O Hjortland, L W Vestermark, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2016
Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 PatientsCamilla B Johnbeck, Ulrich Knigge, Seppo W Langer, et al.
European Journal of Radiology|July 3, 2017
Treatment of multiple test readers in diagnostic accuracy systematic reviews-meta-analyses of imaging studiesTrevor A McGrath, Matthew D F McInnes, Felipe W Langer, et al.
BMC Cancer|January 12, 2020
P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasmsKirstine Nielsen, Tina Binderup, Seppo W Langer, et al.
Pageof 20

Showing results (101-110 of 199) with videos related to

Sort By:
Pageof 20
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of ExcellenceV Grøndahl, T Binderup, S W Langer, et al.
Lung Cancer (Amsterdam, Netherlands)|September 1, 1996
Brain relapses in chemotherapy-treated small cell lung cancer: a retrospective review of two time-dose regimens of therapeutic brain irradiationF Bach, J B Sørensen, L Adrian, et al.
Diagnostics (Basel, Switzerland)|May 11, 2024
Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu/<sup>225</sup>AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the PancreasElisabetta Perrone, Kriti Ghai, Aleksandr Eismant, et al.
Ugeskrift for Laeger|March 15, 1993
[The value of bone marrow scintigraphy in patients with recurrent breast cancer]S W Langer, C Kamby, H S Thomsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 2022
Prospective Phase II Trial of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET/CT Imaging of Integrin α<sub>v</sub>β<sub>3</sub> for Prognostication in Patients with Neuroendocrine NeoplasmsEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2020
Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trialMorten Quist, Seppo W Langer, Christian Lillelund, et al.
Journal of Neuroendocrinology|June 27, 2024
NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasmsH Sorbye, G O Hjortland, L W Vestermark, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2016
Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 PatientsCamilla B Johnbeck, Ulrich Knigge, Seppo W Langer, et al.
European Journal of Radiology|July 3, 2017
Treatment of multiple test readers in diagnostic accuracy systematic reviews-meta-analyses of imaging studiesTrevor A McGrath, Matthew D F McInnes, Felipe W Langer, et al.
BMC Cancer|January 12, 2020
P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasmsKirstine Nielsen, Tina Binderup, Seppo W Langer, et al.
Pageof 20